Hot Life Science Investor Mandate 1: Eastern US Angel Group Targeting Orphan Indications

19 Jul

An angel group based in the Eastern US currently has around $15 million in total assets under management, and is currently deploying capital from its third fund. The firm is looking for new opportunities in the life science space, but has no set timeline to make allocations. The group typically allocates between $250,000 and $2 million per company.

Currently, the angel group is most interested in the biotech therapeutics and medtech space, but only those that are targeting orphan indications. The group will not consider therapeutics and diagnostics that are treating any other indications besides orphan diseases due to the current difficult FDA regulatory framework.

The group is looking for pre-revenue companies within this area. However, they would consider companies in the biotech therapeutics space that have products in the preclinical stage through phase III of development, and in the medtech space the firm is looking for companies that have a product in development, or have a prototype.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: